The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
EPR-Technologies is pursuing development of an unprecedented standard of emergency care when CPR fails
Subscribe To Our Newsletter & Stay Updated
